Rezpegaldesleukin Shows Positive Phase 2b Results for Atopic Dermatitis

Nektar Therapeutics announced The Lancet's publication of positive Phase 2b REZOLVE-AD study results for rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis. The trial met all primary and key secondary endpoints, demonstrating significant improvements in various disease activity measures. These findings support the continued advancement of rezpegaldesleukin into Phase 3 clinical programs.